Introduction
Currently, most anti-inflammatory treatments aim to decrease levels of cytokines responsible for causing symptoms associated with inflammatory diseases such as Crohn's disease and rheumatoid arthritis (RA). Initially, biologic drug therapies targeting TNF-a were developed for the treatment of RA. Early studies aimed at elucidating the role of pro-inflammatory cytokines in RA suggested that impacted joints contained more pro-inflammatory cytokines (especially TNF-a) than normal joints. Subsequent studies showed that blocking TNF could reduce its levels and produce a relief of symptoms in clinical trials using RA patients who had failed current treatments. These trials were the first to show that inhibiting a single cytokine was enough to inhibit the immune activation that led to those inflammatory symptoms in those patients. Shortly thereafter, TNF inhibitors started being used for Crohn's disease with a clear benefit. [1] Crohn's is a chronic systemic illness which primarily affects the gastrointestinal tract. Flare-ups are characterized by an increase in bowel movement frequency, diarrhoea, abdominal cramping, weight loss and fever. Manifestations outside the intestine include rheumatologic symptoms (arthritis, ankylosing spondylitis), dermatologic (skin patches) and ophthalmologic symptoms such as uveitis. Patients may also experience frequent aphthous ulcers in the mouth. [2] Maintenance of inflammatory bowel disease (IBD), including Crohn's, is dependent on the release of pro-inflammatory cytokines, such as TNF-a and IL-6 from immune cells. Murine studies have also identified several environmental and genetic factors which may be involved in the pathogenesis of IBD. These factors have in common their tendency to disrupt intestinal homeostasis leading to Review acute inflammatory responses. Some identified factors include smoking, NSAID use, antibiotic use, infections and diet. Genetic factors include variations leading to increased cytokine production, autoimmunity and altered intestinal microbiota. Recurrent inflammatory events lead to a loss of immune regulatory ability and allow for the development of a chronic inflammatory state. Accordingly, many current successful therapies for IBD include neutralization of these cytokines using biologics in the form of monoclonal antibodies or fusion proteins. [3] In the gut, the main characteristic of Crohn's disease is marked by transmural patches of inflammation in the lamina propria which consists of increased infiltration of lymphocytes. In active disease, this may also include an increase in neutrophils present. As noted, the development of Crohn's may depend on a combination of genetic and environmental factors leading to an exaggerated immune response to commonly encountered antigens as well as commensal flora found in the intestine. Many genes (more than 160) have been described to possibly be altered in patients with IBD, with some describing a direct proinflammatory link resulting in the infiltration of immune cells which cause damage and alteration of the intestinal crypts. [2] NOD2 is one of the genes first described to be responsible for susceptibility to Crohn's and is a receptor normally used for bacterial recognition, leading to NF-kB activation and pro-inflammatory cytokine release. Alternations, particular a truncation, in NOD2 have been thought to result in an ineffective clearing of bacteria or suppression of the innate response, leading to exaggerated inflammation. Because NOD2 expression is found in monocytes and macrophages, the inability of these innate cells to recognize bacteria may result in adaptive immune cells overexaggerating their response to these same bacteria. Alternatively, wild-type NOD2 may mediate release of IL-10 which suppresses the inflammatory response. [4] It has also been suggested that loss of NOD2 function may lead to a lack of inhibition of TLR2, thereby activating inflammatory pathways and an exaggerated Th1 response, which is normally seen in Crohn's. This further suggests that Crohn's is a dysfunction of both innate and adaptive arms of the immune system, among other factors. Th1 cells are induced by IL-12 and produce large amounts of IL-2 and IFN-gamma, which activates TNF-a-producing macrophages. [5] Further, it has been reported that in addition to TLR2, TLR4 and TLR8 are expressed at abnormally high levels in IBD, which may also contribute to inflammation. [6] Chemokines and their subsequent leucocyte recruitment are also thought to be associated with the pathophysiology of IBD. Several chemokines including IL-8, MCP-1 and 3, as well as MIP-1a and MIP-1b have been shown to be expressed in patients with Crohn's or ulcerative colitis. [7] [8] [9] Several studies at the receptor level have been performed on CCR9, in particular, which is a chemokine receptor expressed on thymocytes and lamina propria lymphocytes of the small intestine. CCL25 is an intestine-specific ligand for homing to the small intestine. [10] Leucocyte extravasation into the tissue, including the intestine is mediated by selectins, integrins and chemokines that bind to their chemokine receptors on the surface of infiltrating leucocytes. Chemokines can also facilitate the activation of integrins.
To that end dendritic cell (DC)-activated na€ ıve T cells in the gut-associated lymphoid tissue begin expressing CCR9 as well as a 4 b 7 integrin which in turn stimulates them to migrate back to the intestine. [11] Additionally, CCR2 has been indicated in IBD. More specifically, CD4 + T lymphocytes which are recruited to the ileum in Crohn's disease express CCR2, suggesting that CCR2 blockade may represent a novel therapeutic target in IBD. [12] Similarly, cytokines and an aberrant innate/adaptive response are also associated with the pathogenesis of rheumatoid arthritis. Genetic and environmental factors promote biological conditions including the formation of autoantibodies such as Rheumatoid factor, and anticitrullinated protein antibodies. It appears these can be detected even before evidence of RA sets in, suggesting there is a sequence of inflammatory events leading to inflamed synovial tissue, articular damage and bone erosion. [13] Along with several factors, continued inflammation, propagated by cytokines such as TNF-a, increase articular damage resulting in increased release of self-proteins. Such events, causing prolonged expression of self-molecules outside of their cellular domains, potentiate autoimmune phenomena. Cytokines, therefore, have multiple roles in the development of rheumatoid arthritis, both instigating and propagating inflammatory states, as well as causing immune dysregulation allowing for the development of autoimmunity. [14] With regard to the roles of chemokines in RA, neutrophil trafficking in response to CCL2 has been shown to contribute to bone erosion and articular destruction in RA. Activation of chemokine receptors such as CCR2 which are highly expressed in neutrophils from RA patients has been shown to result in increased neutrophil infiltration into the joints of experimental mice. [15] Studies have also suggested that the synovial compartment contains ligands for CCR1, CCR2 and CCR5 and that blocking these (particularly CCR1) may be beneficial in preventing monocyte migration to the synovial compartment. [16] Evidence also suggests a role for growth factors including GM-CSF in RA inflammatory pathophysiology. GM-CSF is expressed in the synovial membrane and in high levels in the synovial fluid. In RA, it makes sense that GM-CSF contributes to the enhanced function of neutrophils, macrophages, Th17 cells and dendritic cells, all of which can contribute to inflammation seen in the joint. DCs in particular seem to be less influenced by anti-inflammatory IL-10 in the presence of GM-CSF, and continue to produce IL-1, IL-6 and TNF-a, along with macrophages, and RA synovial fibroblasts which secrete IL-6. Because most of these cytokines released in the synovial fluid signal through the JAK/STAT pathway, this pathway is an attractive drug target. Lastly, these continually active DCs will keep presenting autoantigens on MHC molecules, propagating the adaptive immune response in the joint. [17] As in Crohn's disease, studies have elucidated possible roles for TLRs, particularly the endosomal TLRs such as TLR 3, 7, 8 and 9 in the pathogenesis of RA. [18] TLR4 targeting studies have also suggested that there is enhanced expressed of TLR4 and its endogenous agonists in the synovium. [19, 20] To that end, TLR4 blockade in murine and humanized models of RA resulted in reduced levels of TNF-a, IL-1, IL-6 and IL-8, most likely from reduced activation of crucial signalling components including NF-kB, and JAK1. [19] Additionally, polymorphisms in the TLR4 gene have been suggested to be associated with increased susceptibility to RA. [21] In addition to the symptoms encountered by RA patients daily, RA patients also have a higher risk of myocardial infarction, cardiovascular mortality and increased risk of lymphoma. Patients who are able to achieve remission tend to decrease their risk of these, and while biologicals appear to be more effective than the traditional DMARDs like methotrexate, even still, only about two-third of patients experience clinical efficacy with the biologicals. [17] Biologicals also require parenteral administration and are costly to produce. Small molecules which inhibit inflammation tend to be more desirable for the fact that they are more economical to manufacture.
While there are several possible mechanisms of action for the anti-inflammatory therapies commonly used for these disease states, (Figure 1 ), this review will focus on inhibition of cytokine signalling and release as well as decreasing leucocyte activation, chemotaxis and recruitment.
Current Drug Targets TNF inhibition
TNF-a is a major pro-inflammatory cytokine, instigating a wide array of biological activity. Perhaps its most fundamental role is to upregulate the immune response during bacterial encounter, most commonly through Toll-like receptor pathways. [22] TNF-a is secreted by a variety of immune cells, predominantly macrophages and monocytes. Other cells types which produce this cytokine include neutrophils, T cells, and B cells. [23] Altered expression of genes transcribing this cytokine is thought to be a factor involved in several autoimmune disorders by precipitating damaging inflammatory effects to tissues such as cartilage and bone in RA, and to myelin of neurons leading to multiple sclerosis. [24] TNF-a is also implicated in the development of the chronic gastrointestinal inflammation characteristic of IBDs such as Crohn's. Large releases of TNF-a have also been identified as a major inducer of septic shock. [24] High serum levels of TNF-a and soluble TNF receptor (TNFR1) are correlated with increased incidence of inflammatory disease. [25] [26] [27] However, recent efforts of many researchers have insisted that signalling through the TNFR2 mediate cell survival. [26, 27] Regardless of the proposed benefits of TNF-a, it remains clear that abnormal expressions of TNF-a and TNFR are associated with, and can lead to chronic inflammatory conditions. For example, Agarwal and colleagues showed that the presence of a G-to-A polymorphism at position À308 in the promoter region of the TNF-a gene could increase TNF-a transcription up to sevenfold. [28] As such, TNF-a has become a major therapeutic target to help alleviate the inflammatory symptoms of the autoimmune diseases mentioned here. One way in which TNF-a is neutralized is through antibody therapy. Today a handful of commonly used TNF antibodies exist. Perhaps the most popular are the fully human anti-TNF-a monoclonal antibody adalimumab. Others include the TNF receptor fusion protein etanercept, the chimeric mouse/human monoclonal antibody infliximab and the humanized Fab anti-TNF fragment certolizumab. [25] Antibodies are in a class of therapeutic agents known as biologicals. Biological agents are generally much larger and complex in terms of structure than traditional drug molecules. Producing these agents can take a significant amount of time and work, rendering their sale prices very high. For example, the average wholesale price for a 1-month course of adalimumab in 2017 is $7685.02. [29] While these anti-TNF biologicals mainly differ based on absorption and retention Figure 1 Potential mechanisms of action for anti-inflammatory therapies. This review focuses on therapies which inhibit pro-inflammatory cytokine release as well as decrease leucocyte recruitment.
(i.e. pegylated certolizumab), route and dosing (infliximab is dosed mg/kg while others are a fixed dose) some patients have failed to have symptom relief after trying one or even two TNF inhibitors. [30] Failure of anti-TNF therapy to alleviate the symptoms of abdominal pain and frequent diarrhoea in patients with Crohn's disease has been correlated with certain patient characteristics such as smoking and depression. Some argue these symptoms must be due to a non-TNF dependent source of inflammation. [30] While the mechanisms for loss of response to anti-TNF treatment are poorly understood, some explanations offered include poor compliance, bioavailability, underlying infection, neutralization by anti-drug antibodies (ADA), as well as problems with drug pharmacokinetics and pharmacodynamics. It is estimated that nearly half of RA and Crohn's patients who initially responded to infliximab will experience a loss of response. This seems to be associated with the appearance of ADA. [31] While biological agents are an effective means of treating inflammatory diseases, it is clear that they have several limitations, including expense and loss of response. Additionally, they can have significant side effects in patients. For example, many patients cannot tolerate chimeric antibodies due to hypersensitivity reactions to the non-human components of the agent. Another common problem is the associated immunosuppression that results in an increased rate of infection by microorganisms. Additionally, some patients may even experience reactivation of latent infections such as Hepatitis B, Pneumocystis pneumonia and tuberculosis. Lastly, these agents must be administered intravenously or subcutaneously potentially leading to complications related to their administration, such as injection site reactions. [32] 
Non-TNF cytokine targets
There are what seem like an endless number of components to the inflammatory response. Many of these components constitute a cascade of biological events that converge to key steps and compounds. Upregulation of TNF-a transcription is one such key step. It is no wonder then why many patients with different inflammatory disorders respond well to anti-TNF therapy. It is likely that the aetiology of their diseases is related to the production or response of serum TNF-a. However, as mentioned, there are also several patients who do not respond well to this therapy or who experience loss of response. For these patients it seems that targeting other key components of the inflammatory cascade may be more useful.
The interleukin-1 (IL-1) family is a group of pro-inflammatory cytokines involved in the pathogenesis of a number of inflammatory diseases. Natural antagonists for IL-1 are produced as well, with IL-1 receptor antagonist (IL-1Ra) being a major one. The IL-1 family represents another potential therapeutic target, and there are a number of IL-1 inhibitors currently on the market or in development. A couple of these (rilonacept and canakinumab) are used for a group of rare, inherited auto-inflammatory diseases in which IL-1b is overproduced. [33, 34] Anakinra, however, is a recombinant IL-1 receptor antagonist that competitively inhibits IL-1, specifically IL-1a and IL-1b, and is used for the treatment of rheumatoid arthritis (RA) in patients who have failed one or more disease modifying antirheumatic drugs (DMARDs). [35] In addition to IL-1 and TNF-a, IL-6 which is released by T cells and macrophages in response to infection and trauma often contributes to the pathophysiology of inflammatory diseases such as RA. Thus, studies have been demonstrating that anti-IL-6 treatments are also efficacious. One anti-IL-6 monoclonal antibody currently available in the US market for the treatment of severe rheumatoid arthritis is tocilizumab. Tocilizumab is a humanized monoclonal antibody and exerts its effects via inhibition of the IL-6 receptor, which can be both membrane-bound and soluble. [36] Siltuximab, on the other hand, is a chimeric monoclonal antibody that binds to IL-6 itself and is currently approved for the treatment of multicentral Castleman's disease, a rare group of lymphoproliferative disorders characterized by excessive release of pro-inflammatory cytokines. Siltuximab has shown some ability to promote tumour cell apoptosis and may be recommended as a cancer treatment. [37] Several other IL-6 inhibitors, including sarilumab, olokizumab and sirukumab are currently undergoing clinical trials (Table 1) . [38] Novel Drug Targets
Signalling targets
Several studies, including experiments utilizing knockout mice, have outlined the importance of JAK/STAT signalling in cytokine signalling and release in several inflammatory conditions, making these signalling pathways ideal targets for therapy. The approval of tofacitinib, a JAK signalling inhibitor used for various autoimmune disease states, demonstrated that components of immune signalling pathways (of which there are many) can be targets for inhibition by novel compounds or biologicals. While tofacitinib can inhibit all four JAK molecules (JAK 1, 2, 3 and Tyk2), it has specificity for JAK1 and JAK3 and in turn inhibits IL-2R cytokines, as well as IFN-R family cytokines to a lesser extent. For this reason, it is able to produce an effect on both the innate and adaptive immune response. In the ORAL standard trial for RA, patients who had failed methotrexate therapies were given tofacitinib, adalimumab or placebo (plus background methotrexate). At 6 months, those patients on tofacitinib or adalimumab achieved higher ACR20 response rates based on symptom reduction criteria set forth by the American College of Rheumatology. [17] Studies suggest it may be effective in treating ulcerative colitis, but not Crohn's. This may represent another alternative for patients who have failed anti-TNF therapy. [10] Baricitinib represents a new investigational drug which also inhibits JAK1 and JAK2 and has been shown to significantly improve response (even over adalimumab) in RA patients for whom methotrexate was ineffective. Thus, JAK signalling inhibitors may represent novel anti-inflammatory therapies for inhibition of multiple cytokines and signalling pathways. [17, 39, 40] The IL-6 family of receptors, including IL-12 and IL-23 receptors also signal through the JAK/STAT pathway. The IL-12 receptor is expressed by both activated T lymphocytes as well as NK cells, dendritic cells and B lymphocytes. Ligation of IL-12 to its receptor induces NK cells to secrete IFN-c and TNF-a, both of which can activate macrophages. The IL-23 receptor is expressed on T lymphocytes and NK cells and can induce proliferation of Th17 cells. These cytokines and their receptors have been demonstrated to be involved in the chronic inflammation associated with autoimmune disease including Crohn's disease; thus, monoclonal antibodies like ustekinumab, which is currently used for psoriatic arthritis, may represent a therapeutic possibility in Crohn's. Trials of patients who had failed anti-TNF therapies had varying degrees of clinical response when given ustekinumab which were significant over placebo. This suggests that blocking IL-12 and IL-23 may be a novel target in Crohn's disease for patients who are refractory to anti-TNF therapies. [10] Along this same vein, a novel compound known as enaminone E121, has been shown to decrease inflammation via the suppression of multiple cytokines released from lipopolysaccharide-activated human peripheral blood mononuclear cells (PBMCs). Among LPS-activated PBMCs, E121 reduced the release of TNF-a and IL-10, as well as Th1 and Th2 cytokines in phytohemagglutinin (PHA) and CD3-stimulated cells. [41] Based on these previous data, experiments were conducted to determine the effect of enaminone E121 on an LPS-activated macrophage cell line. Further, results indicate that E121 is able to suppress the release of proinflammatory cytokines TNF-alpha and IL-6, as well as moderately decrease total nitric oxide after stimulation with LPS, but not IFN-gamma, indicating that there is a target for this compound in the TLR4 signalling pathway, potentially p38 MAPK. [42] Studies of p38 MAPK inhibition alongside glucocorticoid treatment have suggested that inhibiting p38 can possibly increase glucocorticoid effectiveness by increasing GR nuclear translocation. [43, 44] Thus, inhibiting kinases may increase the efficacy of the glucocorticoid in decreasing pro-inflammatory cytokine release.
It was hypothesized that enaminone E121, (ethyl 4-(4 0 -chlorophenyl) amino-6-methyl-2-oxocyclohex-3-en-1-aote), an anilino enaminone [41] based on its structure may be capable of bending into a four ring-like structure, resembling the four ring structure of a glucocorticoid (Figure 2) . Preliminary studies using RU-486 as a glucocorticoid receptor antagonist, however, have indicated that E121 does not require the glucocorticoid receptor to exert its anti-inflammatory effects. [45] Currently, molecular modelling and simulation experiments are being carried out to confirm this.
With regard to E121 inhibition of cellular signalling, Khajah et al. [42] recently reported the enhancement of tumour necrosis factor receptor-associated factor-2 (TRAF-2) which acts as an adaptor that transmits signals through the TNF receptor superfamily, IL-1 and Toll-like receptors [46, 47] resulting in NF-kB activation (that is required to prevent epithelial cell apoptosis). The TRAF-2 expression in the colon of dextran sulfate sodium (DSS)-treated mice was enhanced, and E121 treatment reduced its expression back to control level. Also, the enhanced total and phosphorylated form of AKT in the colon of DSStreated mice were reduced back to expression control levels by E121 treatment, and the enhanced colonic expression levels of p-ERK1/2 and p38 MAPK post-DSS treatment were reduced to control levels by E121 treatment. Thus, evidence was shown that the anti-inflammatory property of E121 is in part mediated through modulating the activity of pro-inflammatory signalling pathways, colonic epithelial cell apoptosis, neutrophil apoptosis, chemotaxis and superoxide release. [42] Given its potential to decrease pro-inflammatory cytokines such as TNF-alpha and IL-6 in vitro as well as in vivo, E121 may play a role in mitigating cytokines in IBD or RA, without the same adverse effects as glucocorticoids, given their structural differences. Other studies to decrease pro-inflammatory cytokine release via inhibition of signalling have targeted the Tolllike receptor itself. Several studies have been documenting the anti-inflammatory ability of a novel small molecule known as TAK-242, which is a TLR4 inhibitor. [48] [49] [50] Two novel compounds known as C34 and C35 have also been demonstrated to be inhibitors of TLR4 by direct binding. Specifically, molecular modelling studies have shown the pyran ring of the compound directly embeds into the internal pocket of TLR4's co-receptor MD-2. C34 and its b-anomeric cyclohexyl analogue C35 have been demonstrated to not only inhibit TLR4 in macrophages in vitro, but also reduce iNOS in mouse models of endotoxemia and necrotizing enterocolitis (NEC), as well as decrease inflammation ex vivo in resected ileum from infants who suffer from NEC. [51] Like TAK-242, these compounds (Table 1) could represent a novel class of drugs for therapy of disease states in which TLR4 is a major pathophysiological component, like IBD and RA.
Inhibition of immune cell recruitment
Cell adhesion molecule inhibition A major drug target in therapeutic strategies for IBD is leucocyte homing to the intestine, and as such, many recently developed monoclonal antibodies have been aimed at targeting cell adhesion molecules (CAMs) to reduce leucocyte recruitment. CAMs allow cells to bind and interact with their extracellular environment, including other cells. Certain CAMs allow leucocytes to migrate out of general circulation, 'roll' along the surface of vessels, and permeate through tissue to reach sites of inflammation. Two integrin heterodimers a4b1 and a4b7 have been the targets of treatment. Leucocytes expressing a specific CAM, a4b7 integrin, have been implicated in the pathogenesis of IBDs such as ulcerative colitis and Crohn's disease. Cells expressing a4b7 integrin have been shown to exhibit preferential binding to endothelial surfaces of the GI tract. [52] Vedolizumab is a relatively new antibody targeting a4b7 integrin. It inhibits leucocyte binding to the GI tract and significantly decreases the symptoms of IBD. [53] Side effects of vedolizumab include the following infusion related reactions, nasopharyngitis, headache, arthralgia and upper respiratory tract infection. This medication is FDA approved for adult ulcerative colitis and Crohn's disease. Natalizumab is a monoclonal antibody with a similar mechanism of action in that it is an a4 integrin inhibitor (targeting both a4b1 and a4b7) and is used for Crohn's disease and multiple sclerosis (MS). [54] Natalizumab was approved 2004 and was removed from the market due to its risk of causing progressive multifocal leukoencephalopathy (PML), a rare but fatal brain infection caused by JC virus, due to its ability to block a4b1 which targets leucocytes trafficking to the central nervous system. Because of its utility in relapsing MS it was reintroduced to the market in 2006, with strict prescribing under the TOUCH prescribing program. In Crohn's disease, natalizumab performed superior to placebo in clinical trials, with 26% sustained remission rates (vs 16% placebo) after 12 weeks. [10] Vedolizumab, which was approved in 2014, represented a new possibility for integrin inhibition in Crohn's without the risk of PML. In phase III trials, vedolizumab boasted 36% remission rates vs 16% in placebo after 52 weeks. [55] 
Chemokine inhibition
As animal knockout studies have documented the leucocyte chemoattractant ability of certain mediators such as MCP-1 also play a role in chronic inflammation, chemokine signalling is also a potential drug target. CCR inhibitors, including a small molecule called virion, a CCR9 inhibitor for Crohn's disease have undergone trials but have also had issues with efficacy [Pedersen] . Currently there is only one CCR5 antagonist approved (maraviroc) for HIV entry. [56] Preclinical studies have shown possible utility for small molecule blockade of CCR2, a G-protein-coupled receptor which binds MCP-1, a major chemoattractant for monocytes and T cells. Thus, CCR2 antagonists may also be useful therapeutic agents in treating autoimmune diseases in which chemokine signalling plays a role. [57] [58] [59] Studies which have synthesized novel compounds have identified side chains that are able to block CCR2 activity when added to a lead compound. These motifs are N-alkylated piperazine and piperidine, which are closely related structurally (Figure 3a) . [58, 60] Because enaminone E121 was demonstrated to be efficacious in decreasing pro-inflammatory mediators both in vitro and in vivo, a new series of compounds (JODI) was created by incorporating the N-alkylated piperazine motif into the existing E121 pharmacophore (Figure 3b ). It was found that not only was the anti-inflammatory activity of the JODI compounds enhanced when compared to E121, but the JODI compounds also showed CCR2 inhibition activity. [61] Because chemokine receptors, including CCR2 have been shown to play a role in the pathophysiology of Crohn's, [12] this may represent a novel drug target. Studies blocking CCR2 studies have been carried out in RA but have not shown clinical efficacy. [16, 62] 
Conclusion
While many anti-inflammatories exist that have stood the test of time, failure to respond to therapy and adverse effects contribute to the need for new mechanisms of action and drug targets for novel anti-inflammatory agents. Adverse effects, particularly immunosuppression, continue to be of concern with any anti-inflammatory agent. Many novel agents are newly approved, are undergoing clinical trials, or are still in the preclinical stages ( Table 1) . As the immune system represents a complex web of interactions, some of which are redundant, there are nearly an endless amount of drug targets that may be exploited for therapy. Future studies will hopefully be able to help better identify the patients who would benefit from a particular drug action, making therapy for their inflammatory disease state more personalized and effective.
